Servier’s investigational drug sevasemten failed to meet the primary or secondary endpoints in the pivotal GRAND CANYON cohort of a Phase 2 trial for Becker muscular dystrophy (BMD).
The 18-month study compared sevasemten with placebo in 175 adults. The primary measure was the North Star Ambulatory Assessment, which tracks mobility and everyday physical tasks; no statistically significant benefit was found.
Servier said the result did not match some observations from earlier studies. It is analyzing the trial and prior data, but has not yet released detailed results.
The setback comes months after Servier acquired Edgewise Therapeutics’ muscular dystrophy business for $1.55 billion upfront, with up to $1.1 billion in potential milestone payments.
Sevasemten’s future in BMD—and the implications for its Phase 2 development in Duchenne muscular dystrophy—remain unclear. The company reported a favorable safety and tolerability profile in the study.
Sources:
Servier’s $1.6B muscular dystrophy bet on Edgewise delivers quick-fire pivotal failure
Servier’s $1.55bn muscular dystrophy drug fails Phase II BMD trial
Becker and Duchenne muscular dystrophies
Servier’s $1.55 billion muscular dystrophy drug fails first major test
Servier Stumbles in Muscle Disease as Drug From $1.5B Deal Fails Pivotal Test
Servier wagers $2.65bn on Edgewise muscular dystrophy drug
Servier to buy Edgewise Therapeutics’ muscular dystrophy drug
Edgewise to sell muscle dystrophy business to Servier for ...
Servier’s $1.5B bet on Edgewise drug fails five months in
Servier inks $2.6B buyout of Edgewise’s muscular dystrophy unit to beef up neurology pipeline
Servier to Acquire Edgewise Therapeutics Muscular Dystrophy ...